Ilya Yuffa
President, Lilly USA and Global Customer Capabilities
“around 80% of people that are getting treatment are injectable”
“60%-70% being new people that are coming in that have not had access before.”
“We've now increased that to 36,000 prescribers.”
Ilya Yuffa
One-line summary: Runs Lilly USA; the source for US channel mix (injectable vs oral) and Foundayo prescriber expansion.
What they're known for
Brief factual context — fill in.
Why they matter to stock-market
Why this person's claims are tracked here — fill in.
Said
Speaker-attributed claims extracted from diarized sources. Each bullet mirrors one entry in quotes: frontmatter — keep them in sync.
-
On glp1-injectable-supply-chain-bottleneck:
"around 80% of people that are getting treatment are injectable" — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
-
On glp1-injectable-supply-chain-bottleneck:
"60%-70% being new people that are coming in that have not had access before." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
-
On oral-pcsk9-class-disruption, glp1-injectable-supply-chain-bottleneck:
"We've now increased that to 36,000 prescribers." — 2026-08-05-earnings-lly-q2-fy2026 (2026-08-05)
Sources
Related
Cross-links — fill in.